Harvard Bioscience (HBIO) Non-Current Debt (2010 - 2026)

Harvard Bioscience (HBIO) has reported Non-Current Debt for 17 consecutive years, with $36.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Debt changed N/A year-over-year to $36.7 million in Q2 2026; TTM through Jun 2026 was $36.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $35.9 million, changed N/A from the prior year.
• Non-Current Debt was $36.7 million for Q2 2026 at Harvard Bioscience, up from $36.2 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $49.3 million in Q3 2022 and troughed at $35.6 million in Q1 2024.
• A 5-year average of $40.9 million and a median of $38.3 million in 2023 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt increased 12.38% in 2022 and dropped 21.91% in 2023, its largest moves.
• Over 5 years, Non-Current Debt stood at $46.8 million in 2022, then retreated by 21.91% to $36.6 million in 2023, then gained by 3.54% to $37.9 million in 2024, then dropped by 5.25% to $35.9 million in 2025, then gained by 2.26% to $36.7 million in 2026.
• The last three Non-Current Debt figures came in at $36.7 million (Q2 2026), $36.2 million (Q1 2026), and $35.9 million (Q4 2025), per Business Quant data.